BTAI: Important Data Readouts in 2Q23…
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Multiple Data Readouts in 2Q23 BioXcel Therapeutics, Inc. (NASDAQ:BTAI) lead development compound, BXCL501, is c...
18.6 | |
18.29 | |
- | |
18.77 | |
18.08 | |
8.795-34.125 | |
513 M | |
29 010 K | |
375 K | |
-1.95 | |
0 | |
1.1931 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Multiple Data Readouts in 2Q23 BioXcel Therapeutics, Inc. (NASDAQ:BTAI) lead development compound, BXCL501, is c...
BioXcel Therapeutics NEW HAVEN, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- OnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration state...